Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antipsychotic
Pharma
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Cobenfy, a key component in BMS’ plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback in schizophrenia.
Angus Liu
Apr 23, 2025 10:35am
Gilead-backed Lyndra lays off staff as it nears pivotal data
Sep 15, 2023 3:33pm
FDA advisers back Rexulti new use in nearly unanimous vote
Apr 14, 2023 9:24pm
Sanofi offloads rights to prolonged-release antipsychotic drug
Apr 26, 2022 10:18am
Intra-Cellular's Caplyta gains label expansion with bipolar nod
Dec 20, 2021 4:45pm
Amid flurry of settlements, J&J resolves Risperdal claims
Nov 1, 2021 10:45am
